ArticleSchizophrenia research2019
Persistent negative symptoms in individuals at Ultra High Risk for psychosis.
Article in Schizophrenia research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Longitudinal change in neurocognitive functioning in children and adolescents at clinical high risk for psychosis: a systematic review.European child & adolescent psychiatry · 2024Pooled it
- Negative Symptoms and Functioning in Youth at Risk of Psychosis: A Systematic Review and Meta-analysis.Harvard review of psychiatryPooled it
- Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia.Schizophrenia bulletin · 2022Trial
- Baseline psychopathology and relationship to longitudinal functional outcome in attenuated and early first episode psychosis.Schizophrenia research · 2019Trial
- Reinforcement learning deficits in at-risk mental state for psychosis: the role of primary negative symptoms.European archives of psychiatry and clinical neuroscience · 2026Article
- Exploring the Relationship Between Inflammatory Biomarkers and Negative Symptoms Subtypes in Individuals at Ultra-High Risk for Psychosis.Early intervention in psychiatry · 2026Article
- Persistent negative symptoms in the EULAST cohort: impact on functional outcome.Schizophrenia (Heidelberg, Germany) · 2026Article
- Transdiagnostic Symptom Dimensions in Individuals at Ultra-High Risk for Psychosis: Towards Dimensional Representations of Pluripotent Risk.Early intervention in psychiatry · 2025Article
- Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.Schizophrenia (Heidelberg, Germany) · 2025Article
- Persistent negative symptoms in young people at clinical high risk of psychosis treated with an Italian early intervention program: a longitudinal study.European archives of psychiatry and clinical neuroscience · 2024Article
- Longitudinal evaluation on negative symptoms in young people at Ultra-High Risk (UHR) of psychosis: results from a 2-year follow-up study in a real-world care setting.European archives of psychiatry and clinical neuroscience · 2023Article
- Investigation of Neurocognitive Deficits, Quality of Life, and Functional Performance in Ultra-High-Risk Individuals Compared to Familial High-Risk Individuals for Schizophrenia.Iranian journal of psychiatry · 2023Article
- Personality traits and transition to psychosis one year after the first assessment.Frontiers in psychology · 2023Article
- The impact of early factors on persistent negative symptoms in youth at clinical high risk for psychosis.Frontiers in psychiatry · 2023Article
- Effect of Shi-Zhen-An-Shen herbal formula granule in the treatment of young people at ultra-high risk for psychosis: a pilot study.Frontiers in psychiatry · 2023Article
- Negative symptoms in first episode schizophrenia: treatment response across the 2-year follow-up of the "Parma Early Psychosis" program.European archives of psychiatry and clinical neuroscience · 2022Article
- Hindi Adaptation and Psychometric Validation of the Affiliate Stigma Scale.Indian journal of psychological medicine · 2022Article
- Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis.Schizophrenia bulletin open · 2022Article
- The Latent Structure of Negative Symptoms in the General Population in Adolescence and Emerging Adulthood.Schizophrenia bulletin open · 2022Article
- The Relationship Between the Recognition of Basic Emotions and Negative Symptoms in Individuals With Schizophrenia Spectrum Disorders - An Exploratory Study.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Persistent negative symptoms (PNS) defined as negative symptoms that persist for at least six months in the absence of high levels of positive, depressive and extrapyramidal symptoms, are evident early in the course of schizophrenia from the first episode of psychosis. However, their presence even earlier in the illness, in those at Ultra High Risk of psychosis, has not been investigated. In this study, we examined the prevalence, baseline correlates and outcome of PNS in 363 Ultra High Risk individuals. Assessments were conducted at baseline and 2-14 years later (mean follow up time 7.4 years). Baseline assessments included demographic, clinical and neurocognitive measures, which were repeated at follow up. The prevalence of PNS in the UHR group was 6.1%. Poor premorbid social adjustment, deficits in verbal fluency and childhood maltreatment, specifically emotional neglect, were evident at baseline in the PNS group compared to the group without PNS. PNS were associated with poor psychosocial functioning and deficits in processing speed at follow up. Our findings suggest that PNS can be detected early, allowing for the identification of a subset of Ultra High Risk patients who are likely to have poor outcome. These individuals could be the target for specific intervention. Further research is needed into the pathophysiology of these PNS to develop specific interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.